1. Academic Validation
  2. iNOS/NO is required for IRF1 activation in response to liver ischemia-reperfusion in mice

iNOS/NO is required for IRF1 activation in response to liver ischemia-reperfusion in mice

  • Mol Med. 2020 Jun 9;26(1):56. doi: 10.1186/s10020-020-00182-2.
Qiang Du 1 Jing Luo 1 2 Mu-Qing Yang 1 3 Quan Liu 1 4 Caroline Heres 1 Yi-He Yan 1 Donna Stolz 5 David A Geller 6
Affiliations

Affiliations

  • 1 Thomas E. Starzl Transplant Institute, Department of Surgery, University of Pittsburgh, 3471 Fifth Avenue, Kaufmann Medical Building, Suite 300, Pittsburgh, PA, 15213, USA.
  • 2 Department of Surgery, The Second Xiangya Hospital of Central South University, 139 Renmin Middle Road, Changsha, Hunan, People's Republic of China, 410011.
  • 3 Department of Surgery, Shanghai Tenth People's Hospital, Tenth People's Hospital of Tongji University, 301 Middle Yanchang Road, Shanghai, 200072, People's Republic of China.
  • 4 Southern University of Science and Technology, School of Medicine, 1088 Xueyuan Blvd. , Nanshan District, Shenzhen, Guangdong, People's Republic of China, 518055.
  • 5 Department of Cellular Biology, University of Pittsburgh, Pittsburgh, PA, 15213, USA.
  • 6 Thomas E. Starzl Transplant Institute, Department of Surgery, University of Pittsburgh, 3471 Fifth Avenue, Kaufmann Medical Building, Suite 300, Pittsburgh, PA, 15213, USA. [email protected].
Abstract

Background: Ischemia and reperfusion (I/R) induces cytokines, and up-regulates inducible nitric oxide synthase (iNOS), interferon regulatory factor-1(IRF1) and p53 up-regulated modulator of Apoptosis (PUMA), which contribute to cell death and tissue injury. However, the mechanisms that I/R induces IRF1-PUMA through iNOS/NO is still unknown.

Methods: Ischemia was induced by occluding structures in the portal triad (hepatic artery, portal vein, and bile duct) to the left and median liver lobes for 60 min, and reperfusion was initiated by removal of the clamp. Induction of iNOS, IRF1 and PUMA in response to I/R were analyzed. I/R induced IRF1 and PUMA expression were compared between iNOS wild-type and iNOS knockout (KO) mice. Human iNOS gene transfected-cells were used to determine iNOS/NO signals targeting IRF1. To test whether HDAC2 was involved in the mediation of iNOS/NO-induced IRF1 transcriptional activities and its target gene (PUMA and p21) expression, NO donors were used in vitro and in vivo.

Results: IRF1 nuclear translocation and PUMA transcription elevation were markedly induced following I/R in the liver of iNOS wild-type mice compared with that in knock-out mice. Furthermore, I/R induced hepatic HDAC2 expression and activation, and decreased H3AcK9 expression in iNOS wild-type mice, but not in the knock-out mice. Mechanistically, over-expression of human iNOS gene increased IRF1 transcriptional activity and PUMA expression, while iNOS Inhibitor L-NIL reversed these effects. Cytokine-induced PUMA through IRF1 was p53 dependent. IRF1 and p53 synergistically up-regulated PUMA expression. iNOS/NO-induced HDAC2 mediated histone H3 deacetylation and promoted IRF1 transcriptional activity. Moreover, treating the cells with romidepsin, an HDAC1/2 inhibitor decreased NO-induced IRF1 and PUMA expression.

Conclusions: This study demonstrates a novel mechanism that iNOS/NO is required for IRF1/PUMA signaling through a positive-feedback loop between iNOS and IRF1, in which HDAC2-mediated histone modification is involved to up-regulate IRF1 in response to I/R in mice.

Keywords

Histone deacetylase; Inducible nitric oxide synthase; Interferon regulatory factor-1; Ischemia-reperfusion; Nitric oxide; p53 up-regulated modulator of apoptosis.

Figures
Products